Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

3 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Esophagogastroduodenoscopy Week 38 Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Week 38

- 15/07/17 - 1 modulo, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Esophagogastroduodenoscopy Week 16 Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Week 16

- 12/07/17 - 1 modulo, 1 ItemGroup, 3 elementi, 1 linguaggio
ItemGroup: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Week 16.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Esophagogastroduodenoscopy Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Day 1 Pre-Infusion

- 11/06/17 - 1 modulo, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial